MNG465
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.588
- G2M_CHECKPOINT+0.577
- MYC_TARGETS_V2+0.513
- MYC_TARGETS_V1+0.474
- MITOTIC_SPINDLE+0.225
- HEDGEHOG_SIGNALING+0.197
- SPERMATOGENESIS+0.152
- MTORC1_SIGNALING+0.097
- UNFOLDED_PROTEIN_RESPONSE+0.069
- KRAS_SIGNALING_DN+0.062
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.509
- ADIPOGENESIS-0.476
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.415
- FATTY_ACID_METABOLISM-0.405
- INTERFERON_GAMMA_RESPONSE-0.394
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- UV_RESPONSE_DN-0.374
- ANGIOGENESIS-0.366
- PROTEIN_SECRETION-0.345
- OXIDATIVE_PHOSPHORYLATION-0.335
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_W644VEVE | medulloblastoma | — | 0.917 |
| 2 | SRR8613730 | — | D | 0.911 |
| 3 | SRR934968 | — | — | 0.901 |
| 4 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.901 |
| 5 | BS_AM70R8RG | medulloblastoma | — | 0.897 |
| 6 | BS_45J79YTF | high-grade glioma | — | 0.897 |
| 7 | BS_3V3KE3VT | medulloblastoma | — | 0.897 |
| 8 | TCGA-DK-AA6W-01A-12R-A39I-07 | — | — | 0.895 |
| 9 | BS_2Z1MKS84 | medulloblastoma | — | 0.894 |
| 10 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.588 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.577 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.513 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.474 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.225 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.197 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.152 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.097 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.069 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.062 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.032 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.004 | Inavolisib | — uncovered |